<code id='EC68F43DBF'></code><style id='EC68F43DBF'></style>
    • <acronym id='EC68F43DBF'></acronym>
      <center id='EC68F43DBF'><center id='EC68F43DBF'><tfoot id='EC68F43DBF'></tfoot></center><abbr id='EC68F43DBF'><dir id='EC68F43DBF'><tfoot id='EC68F43DBF'></tfoot><noframes id='EC68F43DBF'>

    • <optgroup id='EC68F43DBF'><strike id='EC68F43DBF'><sup id='EC68F43DBF'></sup></strike><code id='EC68F43DBF'></code></optgroup>
        1. <b id='EC68F43DBF'><label id='EC68F43DBF'><select id='EC68F43DBF'><dt id='EC68F43DBF'><span id='EC68F43DBF'></span></dt></select></label></b><u id='EC68F43DBF'></u>
          <i id='EC68F43DBF'><strike id='EC68F43DBF'><tt id='EC68F43DBF'><pre id='EC68F43DBF'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment